High prevalence of hyperkalemia in Brazilian chronic dialysis patients and differences across geographic regions

Prevalência elevada de hipercalemia em pacientes brasileiros em diálise crônica e diferenças entre as regiões geográficas

ABSTRACT

Introduction: Hyperkalemia is a common multifactorial condition of people on chronic dialysis and is associated with mortality. We aimed to inform and discuss the prevalence of hyperkalemia in a large population of chronic dialysis patients in Brazil and its geographic regions. Methods: Prevalence of hyperkalemia (serum potassium ≥6.0 mEq/L) was assessed in the Brazilian Dialysis Survey (BDS) in July 2019, an online survey of voluntary participation in which all dialysis centers registered at the Brazilian Society of Nephrology were invited. Results: Approximately one-third (n=263 of 805) of the Brazilian dialysis clinics participated. The prevalence of hyperkalemia in the whole population was 16.1% (n=7,457 of 46,193; 95%CI=15.8-16.5%), and varied from 12.1% in the North to 18.7% in the Northeast. Conclusion: We found a high prevalence of hyperkalemia in a large Brazilian chronic dialysis population. A nationwide investigation of risk factors, treatment options, and whether this high prevalence contributes to dialysis mortality is warranted.

Keywords: Dialysis; Serum Potassium; Hyperkalemia; Epidemiology.

INTRODUCTION

High serum potassium is a common condition recognized as a risk factor for sudden death and all-cause mortality in the dialysis population. Serum potassium balance is influenced by several factors, including dietary potassium intake (quantity and bioavailability), dialysis parameters (dialysate potassium, bicarbonate, and glucose concentration), medications (β-blockers, heparin, renin-angiotensin system inhibitors (RAAS)), and other conditions (acidosis, insulin deficiency, hyperosmolality). Geographic location and climate parameters can also influence serum potassium levels. In a previous study, the seasonal variability was assessed in a center in an area of tropical-savannah-like climate in Brazil when the highest levels were reported in autumn and the lowest in spring.
Seasonal variations were also reported in studies performed in other countries. Regarding geographic location, a large study from the USA found that patients from the Mediterranean-type climate had higher mean serum potassium than those from areas with continental and subtropical climates.

Brazil has a vast territory with significant variations in climate and cultural habits, and investigations regarding the overall prevalence and distribution of hyperkalemia from a nationwide survey are lacking.

In 2019, the Brazilian Dialysis Survey (BDS), the main source of clinical and epidemiological data on chronic dialysis in our country, included a question about predialysis hyperkalemia status for the first time. Thus, in this brief communication, we aimed to inform and discuss the prevalence of hyperkalemia in chronic dialysis patients in Brazil and its geographic regions.

**METHODS**

**DATA COLLECTION AND ANALYSIS**

Dialysis clinics filled out an online questionnaire (BDS) available on the Brazilian Society of Nephrology (BSN) website. It contained questions about sociodemographic, clinical, and therapeutic variables of patients on chronic dialysis (hemodialysis or peritoneal dialysis). The data for each center were grouped rather than reported individually. To calculate hyperkalemia prevalence (and 95% confidence intervals (95%CI)), we used the informed total number of active patients in the center and those with serum potassium ≥6.0 mEq/L in their routine laboratory analysis in July 2019.

Data collection was performed before the start of a session for hemodialysis patients and during their monthly visit for peritoneal dialysis patients. Participation in the survey was voluntary, and all dialysis centers registered at BSN were invited to participate by email and media. After the initial invitation, additional strategies were used to increase participation, such as monthly reminders emailed to centers.

**RESULTS**

The total response rate of the survey was 39% (314 out of 805 centers). Thirty-three percent (n=263) of the centers answered the question about the number of patients with serum potassium above or equal to 6 mEq/L, totaling data from 46,193 patients. Across the five regions, the lowest response rate was from the Mid-West (n=19 of 76; 25%), followed by the North (n=15 of 46; 32.6%), Northeast (n=49 of 149; 32.9%), Southeast (n=125 of 377; 33.2%), and South (n=55 of 157; 35%) regions. Concerning dialysis modality, 92.7% were on hemodialysis and 7.3% on peritoneal dialysis.

The prevalence of hyperkalemia in the whole population was 16.1% (n=7,457 of 46,193; 95%CI=15.8-16.5%), and the distribution across regions is shown in Figure 1. The North region had the lowest prevalence (n=309 of 2,545; 12.1%, 95%CI= 10.9-13.5%), followed by the Mid-West (n=435 of 3,140; 13.9%, 95%CI= 12.7-15.1%), the South (n=1,049 of 6,875; 15.3%, 95%CI= 14.4-16.1%), the Southeast (n=3,491 of 22,037; 15.8%, 95%CI= 15.4-16.3%), and the Northeast (n=2,173 of 11,596; 18.7%, 95%CI= 18-19.5%) regions.

![Figure 1. Prevalence of hyperkalemia in the whole population and across geographic regions.](image-url)
DISCUSSION

In this analysis, which included approximately one-third of all chronic dialysis patients (n=46,193) in Brazil in July 2019, the prevalence of hyperkalemia was 16.1% and varied across the five geographic regions.

Our overall prevalence was higher than in other populational studies with a similar cutoff for hyperkalemia (≥ 0.6 mEq/L) in hemodialysis patients. In the Dialysis Outcomes and Practice Patterns Study (DOPPS) that included 55,183 patients from 20 countries in 2017, 8% had hyperkalemia,1 while in a large American sample with 74,219 participants in 2007, the prevalence was 4.5%.2 Other results from smaller studies showed a 7.8 and 13% prevalence in a Spanish10 and Greek8 population, respectively.

As stated before, serum potassium is influenced by several modifiable factors. Since we did not collect information regarding these factors in this survey, it is impossible to compare clinical practices with international data.

The lack of control of metabolic acidosis is one of the features that may influence the high hyperkalemia prevalence. Since 1996, the determination of bicarbonate levels has not been included as a compulsory routine laboratory test in the reimbursement package for public hemodialysis patients, making it difficult to detect this often silent condition and implement a treatment when needed.11

Another possible cause is the wide use of hyperkalemic medications. In a Brazilian multicenter study with 195 hemodialysis participants, 53% used beta-blockers and 45% RAAS.12

Changes in dialysis prescriptions by extending dialysis sessions or increasing their frequency, may be difficult to implement due to logistics and public healthcare reimbursement restrictions. It can also affect adequate control of potassium levels.

Regarding dietetic influence, large national epidemiological data and studies performed with Brazilian populations in hemodialysis found a low overall consumption of dietary potassium.13,14 Moreover, other studies have demonstrated a lack of association between dietary and serum potassium in people on chronic dialysis.15,16

The prevalence of hyperkalemia was high in all five regions and ranged from 12.1% in the North to 18.7% in the Northeast, corresponding to a 54% variation.

Unfortunately, the lack of data regarding individual characteristics, dialysis and drug prescriptions, and dietary habits prevent us from investigating possible reasons for the observed differences. The association between dietary and serum potassium has not been extensively studied in Brazilian dialysis patients. There is a marked difference in dietary habits across regions, which could impact potassium levels of dialysis patients.

The results of the DOPPS study showed that serum potassium above 6.0 mEq/L increased arrhythmia by 21% and all-cause mortality by 12 to 33%.9,17 Our results should raise the awareness of the nephrology community to this common life-threatening condition.

We highlight as limitations the electronic data collection by voluntary completion, the grouping of patient data by dialysis center, and the lack of validation of responses. Also, the data were obtained in only one month of the year (July). Therefore, a longer study period is needed to better evaluate the prevalence of hyperkalemia and regional variations. Finally, we could not analyze patients separately by dialysis modality. Since hyperkalemia is probably less common in peritoneal dialysis, the prevalence in hemodialysis may be even higher.

In conclusion, we found a high prevalence of hyperkalemia in a large Brazilian chronic dialysis population. A national investigation of risk factors, treatment options, and whether this high prevalence contributes to dialysis mortality is necessary.

AUTHORS’ CONTRIBUTION

All authors contributed substantially to the conception or design of the study; the collection, analysis or interpretation of data; the writing of the manuscript or its critical review; and the final approval of the version to be published.

CONFlict OF INTEREST

The authors declare that they have no conflict of interest related to the publication of this manuscript.

REFERENCES

1. Genovesi S, Valsecchi MG, Rossi E, et al. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2529–2536.
2. Kovessy CP, Regidor DL, Mehrotra R, et al. Serum and Dialysate Potassium Concentrations and Survival in Hemodialysis Patients. Clin J Am Soc Nephrol 2007; 2: 999–1007.
3. Bansal S, Pergola PE. Current Management of Hyperkalemia in Patients on Dialysis. Kidney Int Reports 2020; 5: 779–789.
4. Hartwig SV, De Oliveira BFA, Da Silva Viana Jacobson L, et al. Seasonal variation of biochemical parameters of hemodialysis patients in a tropical climate area. Mundo da Saude 2019; 43: 566–585.
5. Uswyat LA, Carter M, Thijssen S, et al. Seasonal variations in mortality, clinical, and laboratory parameters in hemodialysis patients: A 5-year cohort study. *Clin J Am Soc Nephrol* 2012; 7: 108–115.

6. Kim Y, Yun SH, Koo H, et al. Different seasonal variations of potassium in hemodialysis patients with high longitudinal potassium levels: A multicenter cohort study using dialysisnet. *Yonsei Med J* 2021; 62: 315–324.

7. Cheung AK, Yan G, Greene T, et al. Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients. *J Am Soc Nephrol* 2002; 13: 2345–2352.

8. Tsiagka D, Georgianos PI, Pikilidou MI, et al. Prevalence, recurrence and seasonal variation of hyperkalemia among patients on hemodialysis. *Int Urol Nephrol*. Epub ahead of print 8 February 2022. DOI: 10.1007/s11255-022-03142-3.

9. Karaboyas A, Zee J, Brunelli SM, et al. Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis* 2017; 69: 266–277.

10. Belmar Vega L, Galabia ER, Bada da Silva J, et al. Epidemiología de la hiperpotasemia en la enfermedad renal crónica. *Nefrología* 2019; 39: 277–286.

11. Rezende LR, Souza PB de, Pereira GRM, et al. Metabolic acidosis in hemodialysis patients: a review. *Brazilian J Nephrol* 2017; 39: 305–311.

12. Morais JG, Pecoits-Filho R, Canziani MEF, et al. Fluid overload is associated with use of a higher number of antihypertensive drugs in hemodialysis patients. *Hemodial Int* 2020; 24: 397–405.

13. IBGE. Instituto Brasileiro de Geografia e Estatística. *Pesquisa de orçamentos familiares 2017-2018: análise do consumo alimentar pessoal no Brasil*. Rio de Janeiro, 2020.

14. Vaz IMF, Freitas ATV de S, Peixoto M do RG, et al. Food intake in patients on hemodialysis. *Rev Nutr* 2014; 27: 665–675.

15. Ramos CI, González-Ortiz A, Espinosa-Cuevas A, et al. Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? *Nephrol Dial Transplant* 2020; 1–9.

16. Bernier-Jean A, Wong G, Saglimbene V, et al. Dietary Potassium Intake and All-Cause Mortality in Adults Treated with Hemodialysis. *Clin J Am Soc Nephrol* 2021; 16: 1851–1861.

17. Karaboyas A, Robinson BM, James G, et al. Hyperkalemia excursions are associated with an increased risk of mortality and hospitalizations in hemodialysis patients. *Clin Kidney J* 2021; 14: 1760–1769.